Natera Officer to Sell $3.31 Million in Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy NTRA?
Source: moomoo
Natera Inc's stock has hit a 20-day low, declining by 4.14% during regular trading hours.
The decline is attributed to the announcement that Officer Daniel Rabinowitz plans to sell 16,798 shares of common stock, valued at approximately $3.31 million. This follows a reduction in his shareholding by 22,892 shares since January 20, 2026, totaling around $5.38 million. Such insider selling can often raise concerns among investors about the company's future prospects.
This stock sale may contribute to negative sentiment around Natera, especially in the context of broader market weakness, as both the Nasdaq-100 and S&P 500 are down significantly.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 199.990
Low
205.00
Averages
262.92
High
300.00
Current: 199.990
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Natera's Signatera Study Published in Clinical Cancer Research
- Study Publication: Natera announced that its Signatera study has been published in Clinical Cancer Research, marking the company's ongoing innovation and development in cancer detection.
- Clinical Impact: The publication of this study may enhance the application potential of Signatera in cancer monitoring, thereby strengthening Natera's market position in the biotechnology industry.
- Scientific Recognition: By being published in a reputable journal, Natera's research has gained recognition in the academic community, further validating the effectiveness and reliability of its technology.
- Future Outlook: The release of this study provides Natera with opportunities to expand its market, particularly in the fields of personalized medicine and cancer treatment monitoring.
See More
Signatera Enables Surgery Avoidance for Women Over 70
- Clinical Study Findings: A prospective study published in Clinical Cancer Research reveals that 68% (23/34) of women over 70 tested MRD-negative with Signatera, and none of these patients experienced disease progression, highlighting Signatera's critical role in early breast cancer management.
- Optimized Treatment Choices: All participants in the study opted for primary endocrine therapy (pET) instead of surgery, indicating that Signatera can assist physicians in providing non-surgical treatment options for older patients, thus balancing disease control with quality of life considerations.
- Significant Monitoring Efficacy: Among the 11 patients who were MRD-positive at baseline, 64% (7/11) cleared their circulating tumor DNA (ctDNA) after 6 months, with all remaining free of distant progression, demonstrating Signatera's effectiveness in monitoring treatment response.
- Positive Patient Feedback: Over 80% of patients reported that Signatera informed their treatment decisions without increasing anxiety, further validating the tool's value in managing older breast cancer patients.
See More
Signatera Assay Enhances High-Risk Patient Management
- ASCC Study Findings: A study involving 84 patients with anal squamous cell carcinoma revealed that Signatera testing correlates strongly with clinical outcomes, as patients who were ctDNA-negative at baseline had a 100% one-year overall survival rate, while ctDNA-positive patients had only 63%, highlighting Signatera's role in recurrence risk assessment.
- LARC Patient Selection: Research on 220 locally advanced rectal cancer patients demonstrated that Signatera can identify high-risk relapse patients, with Signatera-positive non-operative management patients being 4.6 times more likely to require surgical intervention, underscoring the importance of personalized treatment strategies.
- Clinical Outcome Comparison: Post-operative, Signatera-negative patients experienced an 11.5% relapse rate compared to 88.0% for positive patients, indicating the significant clinical value of Signatera testing in guiding surgical decisions and monitoring treatment responses.
- Personalized Monitoring Strategies: Natera's Chief Medical Officer stated that early detection of molecular residual disease through Signatera can support more individualized surveillance and treatment decisions, ultimately improving patient survival rates and quality of life.
See More
Natera (NTRA.US) Officer Plans to Sell $3.31 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Daniel Rabinowitz intends to sell 16,798 shares of its common stock on March 6, with a total market value of approximately $3.31 million.
Reduction in Shareholding: Daniel Rabinowitz has reduced his shareholding in Natera (NTRA.US) by 22,892 shares since January 20, 2026, with a total value of approximately $5.38 million.
See More
Exelixis Aims to Expand Beyond Cabozantinib Franchise
- Significant Revenue Growth: In 2025, Exelixis reported a 7% revenue increase to $2.3 billion, primarily driven by its cabozantinib franchise, which not only solidifies its market position but also funds future research and development efforts.
- Improved Profitability: Earnings per share (EPS) reached $2.78, up 57.9%, reflecting the company's success in cost control and sales growth, which further boosts investor confidence in its financial health.
- New Drug Application Approval: The FDA approved the New Drug Application for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer on February 2, with a final decision expected by December 3, potentially opening new revenue streams for the company.
- Expanded Partnerships: Exelixis has partnered with companies like Takeda and Ipsen to sell cabozantinib in Japan, while also collaborating with Natera for clinical trials of zanzalintinib, enhancing its market penetration and research capabilities.
See More
Exelixis Aims to Become a Top Oncology Player with Expanding Pipeline
- Drug Diversification: Exelixis' lead drug cabozantinib (Cabometyx and Cometriq) is approved for kidney, thyroid, and liver cancers, and is currently in a phase 3 trial for advanced neuroendocrine tumors in the lung, thymus, and gastrointestinal tract, which is expected to enhance its market share.
- New Drug Approval: The FDA approved zanzalintinib in combination with atezolizumab for metastatic colorectal cancer on February 2, with a final decision on its application due by December 3, which could significantly bolster Exelixis' product portfolio if successful.
- Strategic Partnerships: Exelixis collaborates with Takeda and Ipsen to sell cabozantinib in Japan, and has partnered with Natera to utilize its Signatera assay for identifying colorectal cancer patients, enhancing the efficacy of zanzalintinib's clinical trials.
- Strong Financial Performance: In 2025, Exelixis reported a 7% revenue increase to $2.3 billion, primarily from cabozantinib, with earnings per share (EPS) reaching $2.78, up 57.9%, reflecting the company's robust market performance and profitability.
See More
Natera's Signatera Study Published in Clinical Cancer Research
- Study Publication: Natera announced that its Signatera study has been published in Clinical Cancer Research, marking the company's ongoing innovation and development in cancer detection.
- Clinical Impact: The publication of this study may enhance the application potential of Signatera in cancer monitoring, thereby strengthening Natera's market position in the biotechnology industry.
- Scientific Recognition: By being published in a reputable journal, Natera's research has gained recognition in the academic community, further validating the effectiveness and reliability of its technology.
- Future Outlook: The release of this study provides Natera with opportunities to expand its market, particularly in the fields of personalized medicine and cancer treatment monitoring.
See More
Signatera Enables Surgery Avoidance for Women Over 70
- Clinical Study Findings: A prospective study published in Clinical Cancer Research reveals that 68% (23/34) of women over 70 tested MRD-negative with Signatera, and none of these patients experienced disease progression, highlighting Signatera's critical role in early breast cancer management.
- Optimized Treatment Choices: All participants in the study opted for primary endocrine therapy (pET) instead of surgery, indicating that Signatera can assist physicians in providing non-surgical treatment options for older patients, thus balancing disease control with quality of life considerations.
- Significant Monitoring Efficacy: Among the 11 patients who were MRD-positive at baseline, 64% (7/11) cleared their circulating tumor DNA (ctDNA) after 6 months, with all remaining free of distant progression, demonstrating Signatera's effectiveness in monitoring treatment response.
- Positive Patient Feedback: Over 80% of patients reported that Signatera informed their treatment decisions without increasing anxiety, further validating the tool's value in managing older breast cancer patients.
See More
Signatera Assay Enhances High-Risk Patient Management
- ASCC Study Findings: A study involving 84 patients with anal squamous cell carcinoma revealed that Signatera testing correlates strongly with clinical outcomes, as patients who were ctDNA-negative at baseline had a 100% one-year overall survival rate, while ctDNA-positive patients had only 63%, highlighting Signatera's role in recurrence risk assessment.
- LARC Patient Selection: Research on 220 locally advanced rectal cancer patients demonstrated that Signatera can identify high-risk relapse patients, with Signatera-positive non-operative management patients being 4.6 times more likely to require surgical intervention, underscoring the importance of personalized treatment strategies.
- Clinical Outcome Comparison: Post-operative, Signatera-negative patients experienced an 11.5% relapse rate compared to 88.0% for positive patients, indicating the significant clinical value of Signatera testing in guiding surgical decisions and monitoring treatment responses.
- Personalized Monitoring Strategies: Natera's Chief Medical Officer stated that early detection of molecular residual disease through Signatera can support more individualized surveillance and treatment decisions, ultimately improving patient survival rates and quality of life.
See More
Natera (NTRA.US) Officer Plans to Sell $3.31 Million in Common Stock via Form 144
Stock Sale Announcement: Officer Daniel Rabinowitz intends to sell 16,798 shares of its common stock on March 6, with a total market value of approximately $3.31 million.
Reduction in Shareholding: Daniel Rabinowitz has reduced his shareholding in Natera (NTRA.US) by 22,892 shares since January 20, 2026, with a total value of approximately $5.38 million.
See More
Exelixis Aims to Expand Beyond Cabozantinib Franchise
- Significant Revenue Growth: In 2025, Exelixis reported a 7% revenue increase to $2.3 billion, primarily driven by its cabozantinib franchise, which not only solidifies its market position but also funds future research and development efforts.
- Improved Profitability: Earnings per share (EPS) reached $2.78, up 57.9%, reflecting the company's success in cost control and sales growth, which further boosts investor confidence in its financial health.
- New Drug Application Approval: The FDA approved the New Drug Application for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer on February 2, with a final decision expected by December 3, potentially opening new revenue streams for the company.
- Expanded Partnerships: Exelixis has partnered with companies like Takeda and Ipsen to sell cabozantinib in Japan, while also collaborating with Natera for clinical trials of zanzalintinib, enhancing its market penetration and research capabilities.
See More
Exelixis Aims to Become a Top Oncology Player with Expanding Pipeline
- Drug Diversification: Exelixis' lead drug cabozantinib (Cabometyx and Cometriq) is approved for kidney, thyroid, and liver cancers, and is currently in a phase 3 trial for advanced neuroendocrine tumors in the lung, thymus, and gastrointestinal tract, which is expected to enhance its market share.
- New Drug Approval: The FDA approved zanzalintinib in combination with atezolizumab for metastatic colorectal cancer on February 2, with a final decision on its application due by December 3, which could significantly bolster Exelixis' product portfolio if successful.
- Strategic Partnerships: Exelixis collaborates with Takeda and Ipsen to sell cabozantinib in Japan, and has partnered with Natera to utilize its Signatera assay for identifying colorectal cancer patients, enhancing the efficacy of zanzalintinib's clinical trials.
- Strong Financial Performance: In 2025, Exelixis reported a 7% revenue increase to $2.3 billion, primarily from cabozantinib, with earnings per share (EPS) reaching $2.78, up 57.9%, reflecting the company's robust market performance and profitability.
See More
